Progress in diagnosis and treatment of chronic inflammatory demyelinating polyradiculoneuropathy.


Journal

The Lancet. Neurology
ISSN: 1474-4465
Titre abrégé: Lancet Neurol
Pays: England
ID NLM: 101139309

Informations de publication

Date de publication:
08 2019
Historique:
received: 02 08 2018
revised: 05 02 2019
accepted: 25 02 2019
pubmed: 12 5 2019
medline: 9 6 2020
entrez: 12 5 2019
Statut: ppublish

Résumé

Chronic inflammatory demyelinating polyradiculoneuropathy (CIDP) is a rare and heterogeneous but treatable immune-mediated neuropathy. Nerve conduction studies are considered essential for a definite diagnosis, but poor performance and misinterpretation of the results frequently leads to misdiagnosis. Nerve ultrasound and MRI could be helpful in diagnosis. Whereas typical CIDP is relatively easy to diagnose, atypical variants with distinct phenotypes can be a diagnostic challenge. Intravenous or subcutaneous immunoglobulin, corticosteroids, and plasma exchange are effective treatments, but maintenance treatments are often required for years, and treatment regimens require careful and regular adjustments to avoid undertreatment or overtreatment. Patients who do not improve, or insufficiently improve after treatment, might have specific characteristics related to a distinct disease mechanism caused by immunoglobulin G4 antibodies to nodal or paranodal proteins, and could require alternative treatments. Future studies should focus on curative and individualised treatment regimens to improve the patient's condition and to prevent further nerve damage.

Identifiants

pubmed: 31076244
pii: S1474-4422(19)30144-9
doi: 10.1016/S1474-4422(19)30144-9
pii:
doi:

Substances chimiques

Adrenal Cortex Hormones 0
Immunoglobulins, Intravenous 0

Types de publication

Journal Article Review

Langues

eng

Sous-ensembles de citation

IM

Pagination

784-794

Informations de copyright

Copyright © 2019 Elsevier Ltd. All rights reserved.

Auteurs

Carina Bunschoten (C)

Department of Neurology, Erasmus MC, University Medical Center, Rotterdam, The Netherlands.

Bart C Jacobs (BC)

Department of Neurology, Erasmus MC, University Medical Center, Rotterdam, The Netherlands; Department of Immunology, Erasmus MC, University Medical Center, Rotterdam, The Netherlands.

Peter Y K Van den Bergh (PYK)

Department of Neurology, University Hospital St Luc, University of Louvain, Brussels, Belgium.

David R Cornblath (DR)

Johns Hopkins University School of Medicine, Baltimore, MD, USA.

Pieter A van Doorn (PA)

Department of Neurology, Erasmus MC, University Medical Center, Rotterdam, The Netherlands. Electronic address: p.a.vandoorn@erasmusmc.nl.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH